Work for MEI Pharma, Inc.?

Claim Your Profile

MEI Pharma, Inc. Logo Image

MEI Pharma, Inc.

MEI Pharma, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2020 Annual Report and Form 10K

MEI Pharma, Inc.

MEI Pharma, Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

About MEI Pharma, Inc.

51-200 Employees
Based in San Diego, California

MEI Pharma, Inc. (NASDAQ: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options.

Ticker:
MEIP
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol